Palatin Technologies, Inc.
(NYSE Amex Equities : PTN)

( )
PTN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 2.91%69.000.0%$1713.15m
GILDGilead Sciences, Inc. -0.22%73.341.0%$1486.09m
AMGNAmgen, Inc. 0.73%226.431.3%$647.45m
REGNRegeneron Pharmaceuticals, Inc. 1.59%569.912.5%$560.12m
VRTXVertex Pharmaceuticals, Inc. 0.12%284.961.9%$540.88m
NVAXNovavax, Inc. -7.91%46.11102.0%$530.71m
BIIBBiogen, Inc. 0.02%304.531.6%$447.72m
ILMNIllumina, Inc. 1.51%354.703.5%$344.73m
SRNESorrento Therapeutics, Inc. 0.80%5.071.8%$271.93m
SGENSeattle Genetics, Inc. 1.02%155.776.1%$227.64m
ALXNAlexion Pharmaceuticals, Inc. 0.36%101.502.0%$215.96m
CODXCo-Diagnostics, Inc. 2.94%18.550.0%$192.06m
AAgilent Technologies, Inc. 5.24%84.981.6%$187.17m
IMMUImmunomedics, Inc. -0.69%34.4711.0%$184.11m
MGNXMacroGenics, Inc. 0.84%25.376.2%$182.51m

Company Profile

Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, a peptide melanocortin receptor 4 agonist for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.